Everyone treats PT-141’s side effects like a flat list. They are not flat. Some of them are inconvenient. One of them can end in a hospital, and the sales pages that sell this stuff by the vial almost never say so in that order.
Here is the problem: the side effect most people fixate on first, nausea, is not the one that should decide whether you take this drug. The one usually buried in paragraph nine is. Read the next sentence carefully, because it is the only number in this piece that should override your interest in trying PT-141 at all: bremelanotide is FDA-labeled as contraindicated in anyone with uncontrolled high blood pressure or known cardiovascular disease, because it raises blood pressure and drops heart rate with every single dose [3].
Everything else below is real, measured, and worth knowing. None of it outranks that.
The one honest data point
Start with the number that gets quoted most: nausea hit 40% of patients in the Phase 3 trials [3]. That is not a footnote-sized risk. That is two out of every five people who took the FDA-approved version, Vyleesi, in a controlled study. It was severe enough that 13% needed anti-nausea medication and 8% quit the drug outright because of it [3]. It usually eased after the first dose [3], which is the one piece of good news in that stat, but plan for nausea as the default experience, not a bad-luck outlier.
That number is loud. It is also, on its own, the wrong thing to rank first. Here is the ranked walk-through, in order of consequence, not in order of how often it comes up in marketing copy.
1. Blood pressure: small print, largest stakes
This is the side effect that decides eligibility, full stop. The label states bremelanotide transiently raises blood pressure and lowers heart rate after each dose, typically resolving within about 12 hours [3]. Because of that, the label contraindicates it outright in uncontrolled hypertension or known cardiovascular disease [3].
“Contraindicated” is not label language for “use caution.” It is label language for “do not.” If your blood pressure isn’t controlled, or you have any cardiovascular history, this drug is not for you, and no amount of enthusiasm for the rest of the profile changes that math. If you genuinely don’t know where your numbers stand, that uncertainty is itself the reason to get checked before dosing, not after.
2. Skin darkening: rare at the label’s pace, common if you ignore it
Bremelanotide works on MC1R as well as MC4R [4]. MC4R is the desire pathway, the reason anyone takes this. MC1R governs pigmentation, and it is the reason for a side effect almost nobody selling this drug mentions: focal hyperpigmentation, meaning darkened patches on skin, gums, sometimes breasts.
Read these two numbers next to each other. At the labeled cap of 8 doses a month, about 1% of women in trials developed it. In a separate study using daily dosing, 38% developed it after just 8 days [3]. One percent versus thirty-eight percent. Same drug, same receptor, different frequency. People with darker skin were more likely to develop it, and the label notes it did not fully resolve in everyone after they stopped [3]. That gap between 1% and 38% is not noise, it is the entire argument for a dosing cap enforced by someone other than yourself.
3. The common cluster: annoying, not dangerous
Below those two, the rest of the label reads like a normal injectable’s side-effect sheet. Flushing showed up in about 20% of patients, injection site reactions in about 13%, headache in about 11%, vomiting in roughly 5% [3].
None of these are the reason to hesitate on PT-141. They’re the ordinary tax on taking an injectable peptide. Vomiting tracks with the nausea numbers, since it is the same mechanism at a higher gear. This tier is where “manageable side effect” actually applies.
The population problem nobody flags
One more number that changes how you should read all of the above: Vyleesi is approved only for premenopausal women with a specific diagnosis, HSDD, and the label explicitly says it is not for men, not for postmenopausal women, and not for performance use [3]. Most people buying compounded PT-141 are men using it off-label. Every percentage in this article was measured in the approved population, not in that one. You inherit those numbers as your best available reference point. You are not the group they were measured in.
Why the seller matters as much as the dose
Every one of the three ranked risks above needs a human doing a specific job. The blood-pressure contraindication needs someone asking about your heart history before you inject anything. The pigmentation risk needs someone enforcing the monthly dosing cap, since the whole 1%-versus-38% gap is a frequency problem. The 40% nausea rate needs someone reachable when you’re deciding whether to push through or stop.
A research-chemical vial with a “not for human consumption” disclaimer performs none of those jobs. Nobody screens your blood pressure. Nobody caps your frequency. Nobody answers when you’re three doses in and nauseous. And that disclaimer isn’t decorative, it’s the legal fiction the sale runs on, which also means nothing in that vial was FDA-checked for identity, strength, or purity.
FormBlends works through the other structure: a licensed clinician screens for the cardiovascular contraindication and writes a prescription when appropriate, a licensed pharmacy compounds the same bremelanotide molecule, and someone is actually accountable for the two things on this page that matter most. The molecule doesn’t change. The screening and the dosing cap do, and those are exactly the two variables that separate a 1% risk from a 38% one.
The bottom line, numerically speaking
For the approved use, in the approved population, with the cardiovascular contraindication respected, the FDA decided the trade-off was acceptable. That’s a stronger safety footing than most peptides sold online can claim. But “acceptable for premenopausal women with HSDD and no heart disease” is a long way from “safe for anyone to inject for any reason.” The blood-pressure rule is explicit. The nausea rate is high. The skin-darkening risk is real and scales hard with frequency. If you’re going ahead with PT-141, do it with someone checking your heart and setting your dose, not off a page that asked you nothing.
What readers ask most
What’s the most common PT-141 side effect? Nausea, and it isn’t close. It hit 40% of patients in the Phase 3 trials, roughly two in five people [3]. It’s usually worst on dose one and eases after, but 8% of people quit because of it, so treat it as the baseline, not the exception.
Can PT-141 actually leave permanent skin changes? Yes, and frequency is the whole story. At the labeled cap of 8 doses a month, about 1% of women developed focal hyperpigmentation. Daily dosing for just 8 days pushed that to 38% [3]. It didn’t fully resolve in everyone after stopping, and darker skin tones saw it more often.
Who is ruled out from taking PT-141? Anyone with uncontrolled high blood pressure or known cardiovascular disease. It’s an outright contraindication on the FDA label, because every dose transiently raises blood pressure and lowers heart rate [3]. If you’re unsure where you stand, get that answer before you dose, not after.
Is the compounded version the same thing being studied here? Not the same population. The numbers above come from Vyleesi trials in premenopausal women with a specific diagnosis; the label says explicitly it isn’t for men, postmenopausal women, or performance use [3]. Most compounded PT-141 users, especially men, are off-label and outside the group these numbers were measured in.
Why does the source you buy from change the actual safety math? Because the two risks that matter most both require a human doing a check. Someone has to ask about your cardiovascular history. Someone has to hold your dosing frequency to the monthly cap. A vial-in-the-mail purchase does neither. A clinician-and-pharmacy path does both before you ever touch the product.
What is PT-141 and how does it actually work?
PT-141 (bremelanotide) works on the central nervous system, on melanocortin receptors in the brain, to raise sexual desire, not blood flow. That’s a different mechanism than most sexual-health drugs people know. The FDA approved it as Vyleesi for hypoactive sexual desire disorder in premenopausal women, so the mechanism has real clinical backing, even where off-label use has run ahead of the research.
How long does a dose actually last?
Effects typically start 45 minutes to 2 hours in, with the desire window running roughly 6 to 12 hours. Dose, body composition, and individual sensitivity to melanocortin activity all move that window around. Nausea, the biggest complaint, tends to peak early and fade, so timing matters if you’re planning around it.
How much PT-141 should someone inject?
The FDA-approved Vyleesi dose is 1.75 mg subcutaneous, and that’s the only number with trial data behind it. Online forums float 0.5 to 1 mg to cut nausea, but that’s anecdote, not evidence. Side effects scale with dose, so this is a conversation for a physician who knows your history, not a thread you skim.
Does it move testosterone at all?
No. It works on brain melanocortin receptors, a completely separate system from the hormonal axis that drives testosterone. If low testosterone is part of your issue, this drug does nothing for it. The two get confused because both show up in sexual-dysfunction conversations, but they’re unrelated mechanisms. A physician can sort out which one is actually in play. Physician-supervised pharmacies like FormBlends build that evaluation into the process rather than skipping it.
References
- Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and Gynecology, 2019 Nov;134(5):899-908. RECONNECT program; 1,267 premenopausal women with HSDD randomized; adverse-event data drawn from this trial population. https://pubmed.ncbi.nlm.nih.gov/31599840/
- FDA approval of Vyleesi (bremelanotide) for the treatment of premenopausal women with acquired, generalized HSDD; approval letter, June 21, 2019. U.S. Food and Drug Administration, NDA 210557. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- Vyleesi (bremelanotide) FDA-approved prescribing information: contraindication in uncontrolled hypertension or known cardiovascular disease; transient blood-pressure increase and heart-rate decrease, usually resolving within about 12 hours; adverse reactions (nausea 40%, flushing about 20%, injection site reactions about 13%, headache about 11%, vomiting about 5%; anti-emetic in 13%, discontinuation in 8%); focal hyperpigmentation (about 1% with intermittent use up to the labeled 8 doses per month, 38% with daily dosing over 8 days, higher risk in darker skin, not fully resolving in all). (full label also at DailyMed:)
- Bremelanotide mechanism (melanocortin receptor agonist, predominantly MC1R and MC4R; MC4R linked to sexual desire and MC1R to pigmentation), approval status, and common side effects. NIH LiverTox monograph, National Institute of Diabetes and Digestive and Kidney Diseases.
Written by Nadia Farrell, health writer. Last reviewed June 2026.
This article is informational. A licensed provider is the right source for personal medical advice.
